You're missing the point. You need to get this drug in the blood then through the blood brain barrier (BBB) to work in Neuroblastoma, this model shows that it will do that and also has clinical efficacy.
IV dosing generally avoids liver "first pass effect" problems and give higher blood levels with lower doses, less potential adverse effects. All good news in my opinion. Oral dosing may be useful in some cases and slow release and other formulations maybe useful strategies to improve bioavailability.
- Forums
- ASX - By Stock
- KZA
- Ann: Preclinical Studies Justify Mode of Delivery for Anisina
Ann: Preclinical Studies Justify Mode of Delivery for Anisina, page-21
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.